Ironwood Pharmaceuticals, Inc. (IRWD) Income Statement

The quarterly revenue pattern is highly erratic, with 2025Q4 collapsing to $47.7M and 2026Q1 rebounding to $106.5M, indicating that collaboration profit-sharing payments are lumpy. Despite the recent 32.6% YoY jump in 2026Q2, the prior year's declines and the overall trend point to a mature franchise facing pricing and volume pressures. Investors should monitor whether the recent uptick is sustainable or a one-time catch-up.

The 100% gross margin is a structural artifact of the profit-sharing arrangement with AbbVie, not a reflection of underlying product economics. The anomalous quarters with lower gross margins likely include one-time costs or adjustments. Operating margin, however, has improved dramatically from 14.7% in 2024Q1 to 70.2% in 2026Q2, driven by disciplined SG&A and R&D spending, but this may not be sustainable if pipeline investment increases.

The company has demonstrated significant operating leverage, with revenue growth in recent quarters translating into disproportionate profit gains. For instance, 2026Q2 revenue of $113.0M generated $79.3M in operating income, a 70.2% margin, compared to 2024Q1's 14.7% margin on $74.9M revenue. This suggests that the cost base is largely fixed, and incremental revenue flows through to the bottom line, but it also implies that any revenue decline could hit profits hard.

The dramatic reduction in SG&A, from $37.0M in 2024Q2 to $11.3M in 2026Q2, is a primary driver of the margin expansion. This suggests management is cutting marketing and administrative costs, possibly relying more on AbbVie's infrastructure. R&D spending has been relatively flat, indicating a focus on late-stage assets like apraglutide. However, such aggressive cost-cutting may not be sustainable without impairing future growth.